Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide

Checkpoint inhibitors are now entering myeloma clinical trials and are immunotherapy drugs that can be added to existing myeloma treatments. Multiple myeloma puts the brakes on the immune system and these type of immunotherapies remove that brake so the immune system can regain its ability to fight myeloma. Lenalidomide is known to enhance the immune system, so in this study, Genentech is determining whether MPDL3280A (Anti-Programmed Death Ligand 1 [aPD-L1] Antibody)  is most effective with or without lenalidomide. This is a phase I study that is open at 8 myeloma research centers around the United States. The trial objective is to enroll 46 patients.

To find this study on SparkCures, click here:

Anti PDL-1 Antibody Clinical Trial